In a much-awaited decision and probably the first of its kind in India, in the case of Natco v Bayer, the Office of the Controller General of the Indian Patent Office issued a compulsory licence in favour on Natco. Natco now has a non-exclusive and non-assignable licence to Bayer's Indian Patent 215758, for making, using, selling and offering to sell (not importing) the generic version of Nexavar (sorafenib tosylate) within India, for the treatment of kidney and liver cancer. Interestingly, the entire proceeding lasted less than a year and the drug in question was not a life-saving drug.